Gufic BioScience

Gufic BioScience reported a robust Q1 FY26, with total revenue from operations reaching INR 226.9 crores, marking a 10.68% sequential growth from INR 205 crores in Q4 FY25. This growth was largely attributed to the initial contributions from the new Indore facility. The company also demonstrated strong profitability improvements, with EBITDA increasing by 22.96% QoQ to INR 33.2 crores, and EBITDA margin expanding to 14.63% from 13.17%. PBT and PAT also saw significant QoQ increases of 50.92% and 51.25% respectively, reaching INR 16.3 crores and INR 12.1 crores.

The Indore facility is progressing well, having completed 15 vendor audits and secured 145 state FDA approvals. Capacity utilization for lyophilized injectables reached 18-20% in Q1 FY26, with targets to hit 25% by October/November and 30% by Q3 FY26. Management expects the Indore plant to achieve EBITDA breakeven in FY26 and become a margin-accretive asset from FY27. This facility is crucial for tech transfers from Navsari, freeing up capacity for exports, and is designed to meet global regulatory standards, with EU/UK MHRA audits anticipated by Q1 FY27.

The Critical Care division is focusing on scientific engagement and therapy leadership, refreshing its anti-infective portfolio with differentiated combinations. The Sparsh division is undergoing a strategic shift under new leadership, aiming for deeper hospital penetration and a broader high-science offering. While Sparsh currently generates INR 55-56 crores annually, the company targets to grow this to INR 100 crores in the next 2-3 years. Management is re-evaluating Sparsh's direct-to-hospital distribution model due to extended payment cycles (120-180 days), considering a return to a CNF model to improve cash flow.

In the toxin segment (Aesthaderm), Gufic is broadening its portfolio beyond botulinum toxin to include fillers, skin boosters, and biostimulators, with in-licensing discussions underway for a top filler biosimulator brand. Stunnox continues its growth momentum, holding the number two position in India, with a long-term goal to increase its market share to 30-40% from the current 12%. The Ferticare cluster is also strengthening its scientific positioning and selectively introducing differentiated therapies, including the recent launch of an immune therapy for recurrent implantation failure.

Gufic is actively pursuing international expansion, targeting a 5-10% market share in an $824 million addressable market for eight key molecules over the next 3-5 years. Export revenue constituted INR 53 crores in Q1 FY26, representing approximately 20-22% of total revenue. The Navsari Unit 2, which is EU GMP-approved, is currently servicing the UK NHS tender award. The Indore facility is expected to further boost export capabilities, with exports to Southeast Asia and Africa anticipated by December 2025 or early next year, and EU exports by Q1 FY27.

The company acknowledged that working capital will be under pressure for FY25-26 due to the scaling up of the Indore plant and an increase in average payment cycles post-COVID (from 90 to 120 days). Cash flow is expected to remain strained until after FY27. However, management has a clear plan for debt reduction, aiming to become debt-free by 2029. EBITDA margins are projected to face pressure in FY26-27 but are expected to improve from FY27-28 onwards, with a 1% increase anticipated once export share reaches 25%.